☰

Jinrong Cheng, Ph.D. - Publications

Affiliations: 
2005 State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Oncology
Tree Info Similar researchers PubMed Report error

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2006 Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis. Immunological Investigations. 35: 279-96. PMID 16916755 DOI: 10.1080/08820130600745463  0.596
2006 Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Molecular Cancer Therapeutics. 5: 1844-53. PMID 16891471 DOI: 10.1158/1535-7163.Mct-06-0050  0.627
2005 Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. Journal of Translational Medicine. 3: 22. PMID 15943879 DOI: 10.1186/1479-5876-3-22  0.605
2004 Fricke SM, Minderman H, O’Loughlin KL, Cheng J, Repasky EA, Baer MR. Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance. Blood. 104: 4385-4385. DOI: 10.1182/Blood.V104.11.4385.4385  0.595
2004 Cheng J, Hylander BL, Baer MR, Repasky EA. Characterization of the Resistance Mechanisms of HL60 Leukemia Cell Derivatives to Apo2L/TRAIL. Blood. 104: 3412-3412. DOI: 10.1182/Blood.V104.11.3412.3412  0.608
Show low-probability matches.